(Q38070958)

28 August 2017

1 reference

title

Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials (English)

1 reference

28 August 2017

1 reference

Charles A Leath

1

1 reference

28 August 2017

J Michael Straughn

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

30 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

129

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

251-257

1 reference

International incidence rates of invasive cervical cancer after introduction of cytological screening.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

7 January 2021

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

7 January 2021

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Chemotherapy for recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Molecularly targeted therapies in cervical cancer. A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.035

10.1016/J.YGYNO.2012.12.035

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference